Literature DB >> 18310047

Resistance of planktonic and biofilm-grown Burkholderia cepacia complex isolates to the transition metal gallium.

Elke Peeters1, Hans J Nelis, Tom Coenye.   

Abstract

OBJECTIVES: The Burkholderia cepacia complex is a group of pathogens that can cause severe pulmonary infections in cystic fibrosis (CF) patients. The aim of the present study was to investigate the in vitro activity of gallium against planktonic and biofilm-grown B. cepacia complex isolates.
METHODS: Six B. cepacia complex isolates (belonging to three different species) as well as Pseudomonas aeruginosa PAO1 were included in the present study. MICs of Ga(NO(3))(3) for planktonic cells were determined using a broth microdilution method. Biofilms were formed in 96-well microtitre plates, and the fraction of surviving cells following Ga(NO(3))(3) treatment was determined using resazurin as a marker for cell viability. The antimicrobial effect of Ga(NO(3))(3) was assessed in the presence (50 microM) and absence of Fe(3+).
RESULTS: When tested against planktonic cells, the MICs of Ga(NO(3))(3) in the absence of Fe(3+) were 64 mg/L for all B. cepacia complex strains investigated. However, the addition of 50 microM Fe(3+) in the presence of 64 mg/L Ga(NO(3))(3) resulted in increased growth for all B. cepacia complex strains investigated. In sessile cells, resistance to Ga(NO(3))(3) and the extent of the protective effect of 50 microM Fe(3+) against Ga(NO(3))(3) appear to be strain-dependent: the Burkholderia cenocepacia strains investigated are insensitive to Ga(NO(3))(3) in the presence of 50 microM Fe(3+), whereas the presence of Fe(3+) has no protective effect for both Burkholderia multivorans strains investigated.
CONCLUSIONS: As maximal tolerable Ga(3+) levels in plasma are estimated to be approximately 200 microM and considering the high levels of Fe(3+) in the lungs of people with CF, our data suggest that the added value of a Ga(NO(3))(3) treatment of B. cepacia complex-infected patients may be limited.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310047     DOI: 10.1093/jac/dkn072

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

2.  In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii.

Authors:  Luísa C S Antunes; Francesco Imperi; Fabrizia Minandri; Paolo Visca
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

3.  In vitro activity of gallium maltolate against Staphylococci in logarithmic, stationary, and biofilm growth phases: comparison of conventional and calorimetric susceptibility testing methods.

Authors:  Daniela Baldoni; Andrea Steinhuber; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

4.  Using a Chemical Genetic Screen to Enhance Our Understanding of the Antimicrobial Properties of Gallium against Escherichia coli.

Authors:  Natalie Gugala; Kate Chatfield-Reed; Raymond J Turner; Gordon Chua
Journal:  Genes (Basel)       Date:  2019-01-09       Impact factor: 4.096

5.  Loss of O-Linked Protein Glycosylation in Burkholderia cenocepacia Impairs Biofilm Formation and Siderophore Activity and Alters Transcriptional Regulators.

Authors:  Cameron C Oppy; Leila Jebeli; Miku Kuba; Clare V Oates; Richard Strugnell; Laura E Edgington-Mitchell; Miguel A Valvano; Elizabeth L Hartland; Hayley J Newton; Nichollas E Scott
Journal:  mSphere       Date:  2019-11-13       Impact factor: 4.389

6.  Variable Susceptibility to Gallium Compounds of Major Cystic Fibrosis Pathogens.

Authors:  Daniela Visaggio; Emanuela Frangipani; Sarah Hijazi; Mattia Pirolo; Livia Leoni; Giordano Rampioni; Francesco Imperi; Lawrence Bernstein; Raffaella Sorrentino; Francesca Ungaro; Paolo Visca
Journal:  ACS Infect Dis       Date:  2021-12-29       Impact factor: 5.084

7.  Specificity in the Susceptibilities of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus Clinical Isolates to Six Metal Antimicrobials.

Authors:  Natalie Gugala; Dennis Vu; Michael D Parkins; Raymond J Turner
Journal:  Antibiotics (Basel)       Date:  2019-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.